When was Chai Discovery founded?

Chai Discovery was founded in 2023 and became a unicorn in 2025, reaching the milestone in 2 years. It raised its 1st funding round 1 year after its incorporation.

Where is Chai Discovery located?

Chai Discovery is headquartered in San Francisco, United States.

Is Chai Discovery a funded company?

Chai Discovery is a funded company, having raised a total of $630M across 4 funding rounds to date. The company's 1st funding round was a $30M Seed round, raised on Sep 11, 2024.

How much is Chai Discovery worth?

The latest valuation of Chai Discovery is $1.3B as of Dec 15, 2025.

When was the latest funding round of Chai Discovery?

Chai Discovery's latest funding was a $400M Series C round on Jul 14, 2026, with participation from 19 investors.

Is Chai Discovery a Generative AI company?

The primary sectors of Chai Discovery are Generative AI, Life Sciences Tech and Artificial Intelligence.

Where does Chai Discovery rank among its competitors?

Chai Discovery ranks 1st amongst 23 active competitors, of which 13 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Chai Discovery, which secured $400M in Jul, 2026.

Who are the top competitors of Chai Discovery?

Chai Discovery's top competitors include Antiverse, Adimab and Apoha. Among them, Chai Discovery secured the most recent funding round in July, 2026.

Chai Discovery - 2026 Company Profile, Team, Funding & Competitors

Chai Discovery is a series C company based in San Francisco (United States), founded in 2023 by Joshua Meier, Matthew McPartlon, Jacques Boitreaud and Jack Dent. It operates as a Developer of artificial intelligence models for de novo molecular design. Chai Discovery has raised $630M in funding from investors like Sequoia Capital, Index Ventures and General Catalyst, with a current valuation of $1.3B. The company has 23 active competitors, including 13 funded and 2 that have exited. Its top competitors include companies like Antiverse, Adimab and Apoha.

Sectors and market segments that Chai Discovery operate in

Chai Discovery serves in the High Tech, Native AI, HealthTech, Life Sciences market segments.The primary business model of Chai Discovery are:

Company Details

Developer of artificial intelligence models for de novo molecular design. The company focuses on engineering better molecules through advanced computational methods. It introduces new model series designed to achieve high hit rates in antibody design. The company provides access to its technology for molecular research and development.

Website: www.chaidiscovery.com/
Social
Email ID: *****@chaidiscovery.com

Key Metrics

Founded Year

2023

Location

San Francisco, United States

Stage

Series C

Total Funding

$630M in 4 rounds

Latest Funding Round

Series C, Jul 14, 2026, $400M

Post Money Valuation

$1.3B as on Dec 15, 2025

Investors

Sequoia Capital & 29 more

Ranked

1^st among 23 active competitors

Similar Companies

OpenEvidence & 2859 more

View Chai Discovery's full profile

Chai Discovery has raised a total funding of $630M over 4 rounds. Its first funding round was on Sep 11, 2024. Its latest funding round was a Series C round on Jul 14, 2026 for $400M. 19 investors participated in its latest round. Chai Discovery has 26 institutional investors and 4 angel investors.

Here is the list of recent funding rounds of Chai Discovery:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 14, 2026	$400M	Series C	-	-	Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension	Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD Partners, Sapphire Ventures, avra, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook Capital, Avenir Growth Capital, Lachy Groom, Yosemite
Dec 15, 2025	$130M	Series B	$1.3B	-	General Catalyst, Oak HC/FT	Menlo Ventures, OpenAI, Thrive Capital, Neo, Yosemite, Lachy Groom, SV Angel, Emerson Collective, Glade Brook Capital, Dimension
Aug 06, 2025	$70M	Series A	-	-	Menlo Ventures	Anthropic, Yosemite, DST Global, SV Angel, Avenir Growth Capital, DCVC, Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred Ehrsam

Access funding benchmarks and valuations. Sign up today!

View details of Chai Discovery's funding rounds and investors

The founders of Chai Discovery are Joshua Meier, Matthew McPartlon, Jacques Boitreaud and Jack Dent.

Here are the details of Chai Discovery's key team members:

Joshua Meier: Co-Founder of Chai Discovery. They are also an angel investor in 1 startup.
Contact Info: 1 email address
Matthew McPartlon: Co-Founder of Chai Discovery.
Contact Info: 1 email address
Jacques Boitreaud: Co-Founder of Chai Discovery.
Contact Info: 1 email address
Jack Dent: Co-Founder of Chai Discovery.
Contact Info: 1 email address

View details of Chai Discovery's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Chai Discovery include Antiverse, Adimab and Apoha. Here is the list of Top 10 competitors of Chai Discovery, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Chai Discovery 2023, San Francisco (United States), Series C	Developer of artificial intelligence models for de novo molecular design	$630M	Sapphire Ventures, Battery Ventures & 28 others	69/100
2nd	Antiverse 2017, Cardiff (United Kingdom), Series A	Developer of computational platform for de novo design of antibody therapeutics	$20M	Kadmos Capital, ACF Investors & 34 others	67/100
3rd	Adimab 2007, Lebanon (United States), Series F	Antibody discovery and optimization platform for autoimmune and infectious diseases	$35.4M	Polaris Partners, SV Health Investors & 10 others	65/100
4th	Apoha 2021, Bolton (United Kingdom), Series A	Developer of sensory intelligence software to seamlessly anchor machines into physical reality to understand and analyze material behavior	$36M	Singular, Seedcamp & 6 others	60/100
5th	BigHat 2019, San Carlos (United States), Series B	Provider of antibody therapies developed by machine learning and synthetic biology	$148M	S32, Andreessen Horowitz & 13 others	57/100
6th	AbSci 2011, Vancouver (United States), Public	Developer of AI based technology for the production of recombinant protein for therapeutic applications	$228M	Casdin Capital, Redmile Group & 22 others	57/100
7th	LabGenius Therapeutics 2012, London (United Kingdom), Series B	Developer of an automated platform for therapeutic antibody discovery	$69.5M	Atomico, Obvious Ventures & 15 others	56/100
8th	Laigo Biotechnology 2023, Utrecht (Netherlands), Seed	Developer of targeted protein degradation technology for therapeutic applications	$19.8M	Kurma Partners, Curie Capital & 8 others	48/100
9th	Ordaos 2019, New York City (United States), Seed	Provider of an AI accelerator for biomedical research and drug discovery	$21.5M	VTC Ventures, IAG Capital Partners & 5 others	47/100
10th	BioGeometry 2022, Haidian (China), Seed	AI-driven platform developing next-generation programmable protein medicines	-	Jiangmen Ventures, Dachen Capital & 6 others	46/100